therapie
morpholinopropoxy
hemodialysi
rowe
1590
preserved
slight
semnuclmed
advance
investigation
treatment
2318
international
346
proc
oxy
metabolism
600
ottavio
determine
fukazawa
kinuya
dose
IV
EJNMMI
important
beaino
thu
fuchigami
scopu
because
500
dropped
scifinder
177
significantly
characterized
number
gram
incubated
purity
least
will
additional
humana
citation
hsin
modestly
larger
ILAR
lett
radiolabeling
all
specificity
MIRC213
bait
previou
pratama
certain
studied
asses
down
RGD
administration
resulted
cai
vivo
bmcl
pharmacokinetic
intravenou
251
functioned
schuit
1613
747
emitting
015
sampling
higher
quinazolin
existing
WT
2967
way
prior
bra
current
pdf
suspiciou
400
dimethoxyquinazoline
biology
point
should
nonetheles
absence
approx
sci
flank
longer
processe
investigated
excised
022
334
world
00081
tyrosine
chemical
gonzalez
approach
estimated
659
c18
appropriate
itamar
overcome
distinguishable
ERBB4
adult
clin
120
adequate
100
location
operate
cited
inhibitor
2023
360
quantitative
appl
prognostic
encouragement
herz
proces
1010744108
difference
describe
attention
many
fonti
xenografted
ability
338
muzakkir
2013
female
biol
schwab
hirata
H3225
look
kawai
berg
noteworthy
medicine
measure
1089
line
11C
maurer
appear
conducted
2015
cheng
fluor
oid
i19
conclude
chloro
PET
nearly
mousa
int
mafiadoc
technique
bohn
radio
chemistry
concluded
miyazaki
ishiguro
under
creativecommon
behavioral
s11934
deteriorated
similarity
exhibit
256
author
had
toyooka
magnitude
differed
invasive
result
1286
necrotic
adipose
pharmaceutical
context
3167
rep
scitranslmed
annually
created
phase
H520
accounted
generate
word
endometrial
yamane
tetrahydrocannabinol
wild
00559
del19
martinez
kidney
just
drug
more
2147
required
grievink
750
O11CH3
breast
radioiodinated
1248
indicate
shimizu
caac
tissue
injected
highly
trapped
three
why
sumatera
transporter
logarithmic
young
doyle
correspondence
CC
harbor
gelovani
814
million
ACS
resistance
amide
determined
steady
mutational
1603
similar
received
takigawa
rate
apart
appropriately
challenging
14737140
comprehensive
administered
than
method
normal
079
substantially
6369
washout
most
diagnostic
heterogeneity
hydrophobic
BALB
121
increase
heideman
phenoxy
023
oncotarget
metastatic
radiobromine
yexcr
NY
shavrin
whether
could
conventional
18632
18F
1073
castro
creative
state
activation
cho
ito
SUV
integrin
methylindole
month
micro
general
extra
huang
reveal
predict
detect
krasnykh
kimura
semin
eaan8840
constant
non
a750del
verlaan
adolescent
1021
acrylamide
but
set
it
compared
547
tagged
heart
post
s00259
when
ahmed
sensitive
wen
2ftlcr
fluorinated
moderate
potential
they
med
brown
mao
block
33263
deletion
EGF
sensitizing
between
acknowledge
418
strong
nishii
scanning
injection
deeply
intestine
peptide
muammar
amsu
nanobody
support
therefore
biomed
abstract
17251
fluoroethoxy
indirect
susceptible
reducing
finding
mei
designated
aan8840
beside
numerou
H1299
s12943
sample
oet
cause
viewing
medan
catabolism
negative
urol
funding
marker
pyrido
percentage
mole
strange
piomelli
route
365
target
dai
unfavorable
lack
xiao
stigter
having
song
management
oncol
bibliography
culture
iodophenyl
explaining
hsien
soft
6b00520
primary
excretion
s13550
file
developed
selection
fate
meo
structure
E5
feature
HYNIC
quantify
work
resulting
jing
deemed
yoshimoto
pubmed
heterogeneou
xenograft
uptake
growth
kagawa
A549
1609
min
except
EGFR
poot
calculate
2662
technology
compound
washable
nanomed
nanomaterial
york
enhanced
both
owing
1093
inconsistencie
liu
eliminate
substitution
name
xenograft'
undetected
ethyl
emission
pneumol
depending
targeted
2024
containing
pascasio
0072
oct
quotation
trn
CEACAM5
doi
time
response
conclusion
fardon
mechanism
preferential
biointerfaceresearch
biodistribution
422
review
iressa
likely
medium
2016
hindawi
delineated
supported
receiving
stated
rat
discovered
obtained
irreversible
significant
naka
xenobiotics'
infrared
fast
education
acc
triple
missing
124
2018
contralateral
wa
PD153035
insufficient
6360
gambhir
acad
we'd
chem
even
protein
H3255
yloxy
neither
hepatobiliary
picture
blocking
IPQA
saji
date
factor
strategy
respectively
distributed
revealed
68ga
common
guglielmo
kooijman
spleen
however
clinical
typical
detail
single
salim
diagnose
rosa
oka
mcclement
021
biopsy
source
sensitivity
686
1155
okuda
www
solca
FAPI
role
conflict
inhibition
reasonably
nakanishi
nagasaki
domain
lope
minute
PEG6
pegylated
sun
respond
accumulated
standard
reference
acsmedchemlett
anticancer
patient
explained
report
hsieh
optimization
character
amino
followed
hoegnaesbacka
surg
occur
harboring
bioavailability
pretreatment
suggest
651
L747
propertie
revolutionary
distinct
saparuddin
hildebrandt
third
performed
ID
variou
inhibit
MI
miller
colorectal
quoted
distribution
popular
280
four
article
0205
5985
blood
288
introduction
084
prevent
type
natl
showed
cros
237
khomein
indonesia
clear
NSCLC
jnci
media
indicator
furthermore
udayana
E746
iodo
same
methylbenzenesulfonate
regarding
off
CMR
radioactive
methoxyquinazolin
autoradiography
FEE
into
H1650
analysi
BRIAC135
05967
sequencing
1217
period
screening
prostate
blotting
lipophilicity
principal
indicating
ome
3365782240
martin
1210
barrier
filtered
0716
cultured
total
304
valuable
ann
wilcox
reduce
scan
them
application
S416737
pharm
SPECT
effective
info
decision
pna
iommelli
western
given
emulsion
CO
labeled
after
comparison
wang
fawwaz
considerably
kong
material
exon
detected
yang
utara
0088
assay
active
write
makino
need
their
showing
gefitinib
142
jemal
takahashi
demonstrate
monitoring
accumulating
zappa
12998
21763
biointerface
2914
size
keyword
kujtan
aminuddin
TAC
109635
juliu
control
modification
cannabinoid
01757
diethoxy
0042
almost
insertion
brain
distinguish
HCC827
metabolic
minimally
slow
immunotherapy
generation
acros
substantial
advisable
nucmedbio
pang
HN
faculty
download
twofold
arimitsu
declare
lower
modified
one
statu
silva
predictive
establishing
lino
consistent
individual
somewhat
comparable
H1975
kaye
eliminated
efficacy
development
biophysical
inhibited
ijn
pancrea
complement
138
combined
labeling
minna
H358
104
mishani
mishiro
although
notably
663
such
influence
wjcc
submission
rev
characterize
two
increasing
iodoani
acid
alf
decaze
246
better
dongen
lowest
while
zhou
vanden
include
mutant
2020
removing
450
s1806
fat
faster
accumulate
animal'
soghomonyan
figure
variation
full
vector
PM
nishimura
mutation
hydrochloride
leal
very
shown
precise
simple
reported
problem
needed
inclusion
unimodal
retained
each
equivalent
eto
KB
carrier
might
promising
265383
ump
exclusion
CA
effectivenes
proteomic
selectively
PET'
watanabe
structurally
2305
new
app
make
339
nurul
database
license
purpose
PL
bull
fraction
v10
done
2021
among
issue
latu
focu
007
1686
identical
represent
440
shi
only
therapeutic
okazawa
dong
4449
approximately
molecular
remained
concentration
efflux
liao
reversible
miyake
compete
positron
greatest
neuropharm
lung
combination
slobbe
dwi
17588359221146131
capacity
curr
qin
transplanted
particularly
consideration
4470
826
PK
2019
statistically
six
skin
corroborate
anesthesia
subjected
effectively
suzuki
cetuximab
elimination
http
test
QG56
nonspecific
manipulation
radiobrominated
including
mutated
tendency
NH
document
any
diagnosi
well
overview
known
5988
dual
summary
scenario
taken
animal
afatinib'
cancers12020371
responsive
yan
gradually
cellular
initial
A548
internet
discoverie
roy
bound
cannabi
relatively
detecting
left
schreur
131I
bone
stehle
based
da
odani
mukhapadhyay
roth
han
hoek
decreased
there
innovative
singh
discussion
redistribution
erlotinib'
excreted
morpholin
fibroblast
1177
mil
threefold
manually
novel
3322
safe
muscle
40732
mol
los
jin
play
yeh
fluorophenylamino
hydrazinylnicotinate
advantageou
system'
link
university
mice
displayed
maintained
kawasaki
detection
125I
published
high
without
course
PHY
niessen
HPLC
during
plateau
epidermal
unchanged
submitted
selective
noticeable
29832
flag
integrity
reduced
meanwhile
L9
preference
limit
your
bioorg
first
model
stable
curve
inability
molecule
around
organ
baseline
evaluate
term
2017
maximum
here
guo
1016
checkpoint
indicated
retention
against
interfere
mamat
unknown
immediately
something
develop
overall
302
optimally
fluorophenyl
1003
sawazaki
despite
place
2008
utilized
perspective
A431
peak
related
000
polyethylene
cpb
bmc
grime
also
match
overexpression
dtic
TKI
018
death
pyrimidine
vattimo
LP2S
IRS
zhu
ddy
dependence
aim
uday
nuclear
oxycodone
liver
carrying
shiba
altering
assessed
zhang
distinguishing
PC9
early
comparative
about
synthesi
release
jia
transperineal
complexity
tracer'
99mtc
0050
zhao
walsum
qiao
edu
analogue
van
immune
extracted
steadily
pharmacy
emil
proven
alauddin
expert
thermogenic
arg
lee
record
108349
image
kinase
future
rest
parameter
then
eur
direct
namely
decrease
clas
condition
wistuba
1186
reache
1080
evaluated
large
takeda
2500
receptor
ATP
reached
account
reviewed
not
014
identified
site
6_12
US
chosen
TK
varied
implie
become
double
shao
radiopharmaceutical
355
separate
examined
radiosynthesi
vitro
ph15040450
exp
1012
131
injecting
jst
specifically
preclinical
accumulation
activating
cell
increased
junior
300
universita
toward
dirik
cmet
exhibited
employed
modulation
adv
ar500362y
rociletinib
implying
due
before
fundamental
addition
leading
self
good
re
who
care
text
reduction
warrant
recovery
absorption
neuropharmacology
would
second
pal
fold
reasonable
beneficial
dimethylamine
den
potency
ono
recommend
morpholino
siegel
either
casagrande
telese
BMC
see
abourbeh
tracer
allow
acquired
jiang
torren
promise
cold
fluorescence
banerjee
hashimoto
exces
fluoro
extraction
urine
case
1007
113503
stability
fong
RESCA
tong
371
inst
body'
slaughtered
tumor
show
rapid
repeated
regardles
ther
making
HER2
nor
further
paper
observed
glu
mean
research
AZD9291
some
photon
PEG
yagi
06183
pre
contrast
najjar
MPG
ilar
sexe
usually
laboratory
11CH
agent
earlier
associated
carcinoma
group
shigematsu
kai
predicted
makassar
specific
seen
therapy
bind
0007
men
use
using
determining
another
135
version
summarized
696
nature
low
through
montesino
day
bromoanilino
BRIAC145
extensive
other
T790M
nucl
ala
radiotracer
acces
approache
george
portion
rotarod
computed
retain
mouse
favored
derivative
radiosensitizer
FTP2
necessarily
s11307
2011
com
tested
kuo
kazuma
several
amine
differentiate
hour
quinazoline
lepera
001
testing
lim
women
clearer
accepted
L858R
les
small
radiolabeled
continued
alati
145
studie
balatoni
dosage
lodhi
osimertinib
worldwide
overlapping
tomoike
matche
ding
wagle
still
gazdar
present
stomach
pair
comparing
fang
2505
background
PG
tomography
propyl
BY
study
lan
statistic
124I
springer
within
cancer
capable
estimation
isotopologue
our
cell'
FDG
978
search
375
549359
different
rank
metabolomic
GMT
expression
leu
ministry
winuprasith
unlabeled
student
biological
2025
imply
collected
usefulnes
αvβ3
inshishian
must
bpb
muslim
umpir
may
identify
koirala
ijms24032505
create
human
akagi
ogawa
helpful
limitation
demonstrated
volgin
commonly
harbouring
ferroptosi
excluded
tahir
carbon
step
shen
shamni
ha
inorganic
windhorst
improved
A750
value
data
del
selectivity
department
program
following
visualization
glycol
pretreated
variability
produced
binding
vecchio
jian
294
313
turnitin
ethoxy
identifying
56085116100
subramanian
chance
ohmomo
implication
presence
37132015000004531
found
gene
soo
since
incubation
ph14030256
01679
deficit
slightly
ratio
according
table
pursued
volume
count
highest
used
559
2005
radioiodine
radionuclide
NCI
kanai
108
notice
1126
change
rei
kawahara
beige
transl
masdiana
probe
chen
greater
PI
1596030
424
slower
male
throughout
PC14
replacing
jnumed
wulandari
expresse
vugt
radioactivity
occupying
org
jstage
reaching
286
yokokawa
kiyono
imaging
page
CT
motor
entire
sex
3390
1002
anilinoquinazoline
704
acquisition
affinity
pattern
identification
mbq
algorithm
afatinib
122
metab
understand
40740
area
absolute
flore
01139
subsequent
grant
impact
targeting
smit
bearing
already
ochi
transfected
mahler
validated
assessment
caused
ijc
s40336
b13
near
nomura
covalently
wherea
discovery
transcriptomic
renal
liquid
right
open
2014
track
huesti
pomper
carried
feng
dynamic
21037
activity
level
input
molecules25122914
prevented
did
positive
structural
QAR
s12915
actually
evaluation
much
umi
weber
minor
dji055
acknowledgment
undergoing
continue
expressing
APP
shan
meng
experiment
takeyama
necessary
mark
top
treated
kinetic
interest
fujisawa
clearance
publication
per
successfully
H441
out
doe
ying
attenuation
benner
1053
1608
erlotinib
minimal
fundamentally
attribution
lin
2022
over
modulating
102581
strain
megarezky
cover